Kintor Pharmaceutical has dosed the first subject in the Phase II clinical trial of KX-826 (pyrilutamide) to treat male androgenetic alopecia (AGA) in the US.

An androgen receptor (AR) antagonist, KX-826 is a topical drug to treat AGA and acne vulgaris. 

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The randomised, double-blind, placebo-controlled, parallel-group trial will assess the safety and efficacy of KX-826 to treat AGA in nearly 120 adult males. 

The change from baseline in non-vellus target area hair counts (TAHC) at week 24 is the trial’s primary endpoint.

In July last year, the US Food and Drug Administration had granted approval to commence phase II trial of KX-826 for AGA in the country. 

See Also:

The company reported that the Phase II trial of KX-826 in adult male AGA patients met the primary endpoint in September last year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

KX-826 also demonstrated safety profile. 

Kintor Pharma founder, chairman and CEO Dr Youzhi Tong said: “As a topical AR antagonist, KX-826’s Phase I and Phase Ib clinical trials in the US have demonstrated a preliminary positive safety, pharmacokinetics and tolerability profile in dosing frequency. 

“KX-826 has showed good efficacy and safety profile in the Phase II clinical trial in China for the treatment of AGA male patients. 

“We look forward to accelerating the clinical process of KX-826 and benefiting more people suffering from hair loss in China and globally.”

In February this year, the company dosed the first subject in a Phase I trial of GT20029 (gel) in the US for AGA and acne.

The double-blind, randomised, parallel-group, placebo-controlled, dose-escalation trial is designed to evaluate the safety, tolerability and pharmacokinetics of GT20029.